Gossamer Bio logo
Gossamer Bio
GOSS | NASDAQ
Chart Builder DCF Calculator
$10.98
+$0.01 (+0.09%)
At close: Nov 16, 2026, 4:00 PM ET
$10.98
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:39 PM ET

Gossamer Bio Company Profile

Company profile explained

Company Profile

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Key Executives

Name Position
Faheem Hasnain Co-Founder, Chief Executive Officer, President & Chairman
Bryan Giraudo Chief Operating Officer & Chief Financial Officer
Caryn L. Peterson Chief Development Officer
Christian Waage Executive Vice President, Technical Operations & General Counsel
Conor O'Donovan Senior Vice President of Regulatory Affairs
Deanna Weber Executive Vice President of Human Resources
Jean-Marie Bruey Senior Vice President of Translational Medicine & Research
Jeanine Anthony Senior Vice President of Marketing
Kelly Dawson Senior Vice President & Program Team Lead
Robert F. Roscigno Senior Vice President of Clinical Development of Pulmonary Vascular Disease
Robert Smith Chief Commercial Officer

Latest SEC Filings

Date Type Title
Oct 29, 2026 SC 13D/A [Amend] Filing
Oct 28, 2026 8-K Current Report
Oct 08, 2026 SC 13D/A [Amend] Filing
Sep 28, 2026 SC 13D/A [Amend] Filing
Sep 28, 2026 8-K Current Report
Sep 25, 2026 4 Filing
Sep 25, 2026 4 Filing
Sep 25, 2026 4 Filing
Sep 25, 2026 4 Filing
Sep 25, 2026 4 Filing
View All SEC Filings ➞
Gossamer Bio
Gossamer Bio logo
Country United States
IPO Date Feb 8, 2019
Industry Biotechnology
Sector Healthcare
Employees 162
CEO Faheem Hasnain

Contact Details

3115 Merryfield Row San Diego, California 92121 United States

Stock Details

Ticker Symbol GOSS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001728117
CUSIP Number 38341P201
ISIN Number US38341P2011
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.